Project Details
Description
A Single-arm, Phase 2 Study to Evaluate the Safety and Efficacy of IMMU-132 in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on Second Generation AR-Directed Therapy
Status | Finished |
---|---|
Effective start/end date | 12/1/18 → 6/30/19 |
Funding
- PROSTATE CANCER CLINTRIAL CONSORTIUM LLC
- IMMUNOMEDICS, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.